SLN124: SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA).
Placebo: sodium chloride, solution for injection
Study summary
This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK), and Pharmacodynamic (PD) response of SLN124.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Phase 1 and Phase 2
Inclusion Criteria:
* Male and female patients aged 18 years or older.
* A confirmed diagnosis of PV according to the revised 2016 World Health Organization criteria:
* Suitable phlebotomy history
* Must agree to adhere to appropriate contraception requirements
* Patients who are not receiving cytoreductive therapy must have been discontinued from any prior cytoreductive therapy for at least 24 weeks before dosing and have recovered from any adverse events due to cytoreductive therapy.
* Patients receiving cytoreductive therapy with hydroxyurea, interferon, busulfan or ruxolitinib must have received a stable dose of cytoreductive therapy for at least 12 weeks before dosing and with no planned change in dose.
* Patients must have had a dermatological examination within 28 weeks prior to dosing.
* Must have an Eastern Cooperative Oncology Group score of 0, 1, or 2.
Exclusion Criteria:
Phase 1 and Phase 2
* Drug intolerance:
1. History of intolerance to oligonucleotides, or GalNAc, or any component of SLN124.
2. History of intolerance to s.c. injections.
* Clinically significant thrombosis (e.g., deep vein thrombosis or splenic vein thrombosis) within 12 weeks of screening.
* History of major bleeding events and/or a requirement for blood transfusion therapy owing to bleeding in the last 6 months prior to screening.
* Meets the criteria for post-PV myelofibrosis as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment
* Any investigational drug less than 6 weeks prior to the first dose of study drug or not recovered from effects of prior administration of any investigational agent.
* Any investigational or marketed product using GalNAc targeting less than 48 weeks prior to administration of any investigational agent (excludes patients with PV who participated in Phase 1 of this study).
* Clinically significant co-morbidities
* Biochemical and hematological parameters:
1. Biochemical evidence of significant liver disease during screening
2. Phase 1: Hematological parameters at screening as follows: platelets \> 1,000,000/µL; or white blood cell (WBC) count \> 25,000/µL; or peripheral blasts \> 1%.
b. Phase 2: Hematological parameters at screening as follows: platelets \> 1,000,000/µL; or WBC count \> 30,000/µL; or peripheral blasts \> 1%.
Primary outcome measure(s)
Phase 1: Incidence of treatment-emergent adverse events (AEs) — Day 239 Safety and tolerability will be reported separately following open-label dose escalation phase and double-blind phase
Phase 1: Assessment of the number of phlebotomies at intervals — 6 months prior to dosing to Day 239
Phase 2: Proportion of patients who achieve response between week 18 and week 36 (placebo controlled double blind phase) — 18 to 36 weeks
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.